TIRZEPATIDE (Mounjaro, Zepbound) prior authorization at UPMC Health Plan
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
UPMC Health Plan requires Glucose-dependent Insulinotropic Polypeptide Receptor Agonist prior-authorization documentation for TIRZEPATIDE (Mounjaro, Zepbound): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return on the clock printed in the current member-specific payer source; if denied, use the appeal window printed on the denial notice to appeal.
The PA criteria you'll need to meet
UPMC Health Plan reviews TIRZEPATIDE (Mounjaro, Zepbound) prior authorizations against its medical policy for Glucose-dependent Insulinotropic Polypeptide Receptor Agonist. UPMC Health Plan-specific context: Integrated payer-provider arm of UPMC (~4M members). Western PA dominant. The Highmark-UPMC consent decree (expired June 2019) governed cross-network access historically; subsequent commercial agreements maintain some access. PA Insurance Department oversight.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in Glucose-dependent Insulinotropic Polypeptide Receptor Agonist
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- UPMC Health Plan's medical policy URL referenced in the cover letter
Denial scenarios to check against the current policy
These are preparation scenarios, not frequency claims. Use only those supported by the current member-specific source:
- Highmark-vs-UPMC network access disputes (historical PA consent decree)
- Specialty drug PA
- Behavioral health prior auth
- Out-of-network reductions
TIRZEPATIDE (Mounjaro, Zepbound)-specific review scenarios and context
Check whether the current notice cites any of these label-, REMS-, or policy-related scenarios:
- Weight-loss exclusion (Zepbound)
- Step therapy requiring GLP-1 first
- Quantity limit
Sold as Mounjaro (T2D) and Zepbound (chronic weight management). Dual GIP/GLP-1 receptor agonist.
Manufacturer patient-assistance program: Lilly Cares — relevant when an UPMC Health Plan denial sticks and the patient needs bridge access while appealing.
How UPMC Health Plan approaches GLP-1 receptor agonists PAs
For TIRZEPATIDE (ZEPBOUND), check whether the current UPMC Health Plan GLP-1 receptor agonists policy cites specialty drug pa. Pharmacy-benefit review for TIRZEPATIDE (ZEPBOUND) at UPMC Health Plan is routed through UPMC Pharmacy Network (in-house, integrated payer-provider). The applicable review clock depends on the member's current product, whether the request is complete and urgent, and governing plan rules. Confirm receipt and timing with UPMC Health Plan; if denied, use the filing date and route printed on that denial notice. The current UPMC Health Plan policy may distinguish T2D-indication PAs (Ozempic, Mounjaro, Trulicity) from weight-management-indication PAs (Wegovy, Zepbound, Saxenda); verify any benefit-exclusion language in the member product. UPMC Health Plan is domiciled in PA, so unresolved appeals escalate to the PA insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead).
If the PA is denied
Verify the appeal window and decision clock in the current denial notice and member-specific payer source before relying on either. Submit through the provider portal (https://www.upmchealthplan.com/providers) with the same packet plus an applicable, current clinical source supporting TIRZEPATIDE (Mounjaro, Zepbound)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal an UPMC Health Plan denial on DenialHelp.
Contact UPMC Health Plan
- Provider portal: https://www.upmchealthplan.com/providers
Frequently asked questions
What documentation does UPMC Health Plan need for TIRZEPATIDE (Mounjaro, Zepbound) prior auth?
UPMC Health Plan's typical PA packet for TIRZEPATIDE (Mounjaro, Zepbound): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For Glucose-dependent Insulinotropic Polypeptide Receptor Agonist, expect clinical-criteria documentation specific to this class.
What's the turnaround time at UPMC Health Plan?
Verify the decision clock in the current member-specific payer policy and request receipt. Product type, urgency, state law, and plan terms can change the applicable timing; this page does not supply an operational deadline.
What documentation issues should be checked for TIRZEPATIDE (Mounjaro, Zepbound) at UPMC Health Plan?
Preparation scenarios to check against the current notice and policy include: Highmark-vs-UPMC network access disputes (historical PA consent decree); Specialty drug PA; Behavioral health prior auth. These are not measured frequency claims. For TIRZEPATIDE (Mounjaro, Zepbound), verify whether the actual denial raises step therapy, indication, or another plan-specific criterion before responding.
Why does UPMC Health Plan require specific BMI documentation for TIRZEPATIDE (ZEPBOUND)?
UPMC Health Plan's GLP-1 prior-auth policy distinguishes T2D-indication submissions (A1C-based criteria) from weight-management-indication submissions (BMI ≥30, or ≥27 with weight-related comorbidity, matching the FDA label). For weight-management TIRZEPATIDE (ZEPBOUND) the reviewer also screens for the plan's anti-obesity-medication exclusion — submit the chart note with BMI, weight-related comorbidity (HTN, dyslipidemia, T2D, OSA, OA), and either (a) documented lifestyle intervention or (b) a documented reason intensive lifestyle was inappropriate. Verify current criteria and timing in the member-specific payer source. Pharmacy-benefit handling is routed through UPMC Pharmacy Network (in-house, integrated payer-provider). External-review escalation for UPMC Health Plan fully-insured policies sits with the PA insurance department.
How do I prep for a peer-to-peer with UPMC Health Plan on TIRZEPATIDE (Mounjaro, Zepbound)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the TIRZEPATIDE (Mounjaro, Zepbound) PA packet
Open ApprovalHelp — generate a TIRZEPATIDE (Mounjaro, Zepbound) prior-auth packet tailored to UPMC Health Plan's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com